Objectives: The effects of ximelagatran, an oral direct thrombin inhibitor (DTI), recombinant hirudin (r-hirudin) and enoxaparin on thrombin generation and platelet activation were studied in humans.
Background: Recombinant hirudin (parenteral DTI) and enoxaparin (low molecular weight heparin) have been demonstrated to be clinically effective in acute coronary syndromes. Ximelagatran is currently under investigation for the prevention and treatment of thromboembolism. The shed blood model allows for the study of thrombin generation and platelet activation in humans in vivo.
Methods: This was an open-label, parallel-group study involving 120 healthy male volunteers randomized to receive one of three oral doses of ximelagatran (15, 30 or 60 mg), r-hirudin (intravenous) or enoxaparin (subcutaneous) at doses demonstrated to be clinically effective in acute coronary syndromes, or to serve as a control. Thrombin generation (prothrombin fragment 1+2 [F1+2] and thrombin-antithrombin complex [TAT]) and platelet activation (beta-thromboglobulin [beta-TG]) biomarkers were studied using a shed blood model involving blood collection from skin incisions made using standardized bleeding time devices.
Results: Oral ximelagatran, intravenous r-hirudin and subcutaneous enoxaparin rapidly and significantly (p < 0.05) decreased F1+2, TAT and beta-TG levels in shed blood, indicating inhibition of thrombin generation and platelet activation. Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected. Melagatran showed dose-proportional pharmacokinetics with low variability. All drugs were well tolerated.
Conclusions: Oral administration of the DTI ximelagatran resulted in a rapid inhibition of both thrombin generation and platelet activation in a concentration-dependent manner using a human shed blood model. The inhibition of thrombin generation by 60 mg ximelagatran was comparable to that observed with doses of r-hirudin and enoxaparin demonstrated to be effective for the treatment of acute coronary syndromes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0735-1097(02)02868-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association between short-term apparent temperature exposure and human coagulation: A time-series study from Beijing, 2014-2023.
Environ Int
January 2025
Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing 100191, China; Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, School of Public Health, Peking University, Beijing 100083, China.
A growing body of evidence suggests that non-optimal ambient temperatures are associated with increased incidence rate and mortality of thromboembolic diseases. We aim to investigate the association between apparent temperature (AT) and coagulation, which is a central pathological link in the formation of thrombi. In this study, we conducted a time series analysis using data from 18,894 participants collected from a health check-up center in Beijing between 2014 and 2023, and validated our findings using 20,549 participants from an andrology outpatient clinic.
View Article and Find Full Text PDFIsolation of Quick-Response High-Affinity Aptamers for Continuous and Reagentless Detection of Thrombin.
Anal Chem
January 2025
Department of Chemistry, Capital Normal University, Xisanhuan North Road. 105, Beijing 100048, China.
Continuous and reagentless biomolecular detection technologies are bringing an evolutionary influence on disease diagnostics and treatment. Aptamers are attractive as specific recognition probes because they are capable of regeneration without washing. Unfortunately, the affinity and dissociation kinetics of the aptamers developed to date show an inverse relationship, preventing continuous and reagentless detection of protein targets due to their low dissociation rates.
View Article and Find Full Text PDFIntegrating biomarkers for hemostatic disorders into computational models of blood clot formation: A systematic review.
Math Biosci Eng
December 2024
Laboratory of Optimization, Design, and Advanced Control, School of Chemical Engineering, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
In the pursuit of personalized medicine, there is a growing demand for computational models with parameters that are easily obtainable to accelerate the development of potential solutions. Blood tests, owing to their affordability, accessibility, and routine use in healthcare, offer valuable biomarkers for assessing hemostatic balance in thrombotic and bleeding disorders. Incorporating these biomarkers into computational models of blood coagulation is crucial for creating patient-specific models, which allow for the analysis of the influence of these biomarkers on clot formation.
View Article and Find Full Text PDFFactor VIIa - antithrombin complexes are increased in asthma: relation to the exacerbation-prone asthma phenotype.
Thromb Haemost
January 2025
Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland.
Background: Asthma is associated with a prothrombotic state. Plasma factor VIIa-antithrombin complex concentrations (FVIIa-AT) indirectly reflect the interaction of tissue factor (TF) with FVII. Since TF is a key initiator of coagulation in vivo, we hypothesized that FVIIa-AT are higher in asthma.
View Article and Find Full Text PDFMice with Reduced PAR4 Reactivity show Decreased Venous Thrombosis and Platelet Procoagulant Activity.
J Thromb Haemost
January 2025
Case Western Reserve University, School of Medicine, Department of Pharmacology, Cleveland, OH United States. Electronic address:
Background: Hypercoagulation and thrombin generation are major risk factors for venous thrombosis. Sustained thrombin signaling through PAR4 promotes platelet activation, phosphatidylserine exposure, and subsequent thrombin generation. A single-nucleotide polymorphism in PAR4 (rs2227376) changes proline to leucine extracellular loop 3 (P310L), which decreases PAR4 reactivity and is associated with a lower risk for venous thromboembolism (VTE) in a GWAS meta-analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!